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Abstract
Background: Human herpesvirus-8 (HHV-8) is linked to the pathogenesis of Kaposi's sarcoma
(KS), and the HHV-8 DNA load in peripheral blood mononuclear cells (PBMC) is associated with
the clinical stage of KS. To examine the expression of HHV-8 in PBMC, four HHV-8 mRNA specific
NASBA assays were developed
Methods: We have developed four quantitative nucleic acid sequence-based amplification assays
(NASBA-QT) specifically to detect mRNA coding for ORF 73 (latency-associated nuclear antigen,
LANA), vGCR (a membrane receptor), vBcl-2 (a viral inhibitor of apoptosis) and vIL-6 (a viral
growth factor). The NASBA technique amplifies nucleic acids without thermocycling and mRNA
can be amplified in a dsDNA background. A molecular beacon is used during amplification to enable
real-time detection of the product. The assays were tested on PBMC samples of two AIDS-KS
patients from the Amsterdam Cohort.
Results:  For all four assays, the limit of detection (LOD) of 50 molecules and the limit of
quantification (LOQ) of 100 molecules were determined using in vitro transcribed RNA. The linear
dynamic range was 50 to 107 molecules of HHV-8 mRNA. We found HHV-8 mRNA expression in
9 out of the 10 tested samples.
Conclusion: These real-time NASBA assays with beacon detection provide tools for further study
of HHV-8 expression in patient material.
Background
Homosexual men infected with HIV-1 are at increased risk
for developing AIDS-related Kaposi's sarcoma (AIDS-KS)
due to co-infection with HHV-8, a gamma herpes virus.
Also known as Kaposi's sarcoma associated herpes virus,
HHV-8 was first discovered in 1994 in KS-affected tissue
[1]. Since then it also has been associated with the devel-
opment of multicentric Castleman's disease and primary
effusion lymphoma (PEL) [2–5]. HHV-8 DNA has been
detected in both tissues and bodily fluids [6,7]. Studies in-
itially focused on HHV-8 and its association with KS,
transmission of HHV-8, and the natural history of HHV-8
infection. As shown by Renwick et al. and Jacobsen et al.
[8,9] seroconversion for HHV-8 during HIV infection in-
creases the risk of developing KS, implying that HIV-1 has
an impact on HHV-8. Laboratory assays developed for the
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detection of HHV-8 include serologic assays such as im-
munofluorescence antibody assays [10–13], immunoblot
assays [10], and various enzyme immunoassays [14–16].
PCR-based assays have also been used to detect HHV-8
DNA [1]. With the serologic assays, sensitivity and specif-
icity are always problematic. No single assay is completely
sensitive and specific [17].
We would prefer a method using viral RNA or DNA as a
marker for the presence of HHV-8. Though DNA is an ob-
vious choice because HHV-8 is a DNA virus, we have cho-
sen RNA, because it indicates activity of the virus and may
thus be a better prognostic marker. Active infected cells
produce more RNA than DNA. In situ hybridisation has
shown that most HHV-8 infected cells in KS lesions are la-
tently infected [18,19]. but lytic HHV-8 infection is clearly
present in a small proportion of cells [20–22].
A method for the detection of RNA is RT-PCR. To increase
sensitivity an additional amplification step can follow the
RT-PCR. This method is time consuming and also increas-
es the likelihood of false positive reactions due to cross-
contamination. Nucleic acid sequence-based amplifica-
tion (NASBA) is a single-step isothermal RNA-specific am-
plification process [23] that amplifies mRNA in a dsDNA
background [24]. NASBA has proved successful in the de-
tection of various mRNAs [24–26] and in the detection of
both viral [23] and bacterial [27] RNA in clinical samples.
By combining the standard NASBA technology [28] with
a molecular beacon that anneals during amplification to
the target sequence, a real-time detection system is gener-
ated [29]. This paper describes our development of real-
time NASBA assays to quantify four functionally different
genes of HHV-8: ORF 73, a latent gene, vGCR, a constitu-
tively active gene, and the lytic genes vBcl-2 and vIL-6. To
normalise the input mRNA we developed a fifth NASBA
for a constitutively expressed mRNA, U1A mRNA, and
standardised the specific HHV8 mRNAs to the expression
of U1A mRNA.
Methods
HHV-8 genes
Our first assay was developed for ORF 73 and is based on
the amplification of a 192 bp fragment situated within the
gene. ORF 73 encodes the major immunogenic latency-as-
sociated nuclear antigen (LANA) of HHV-8. LANA is es-
sential for maintenance of this virus in latently infected
cells [30,31]. It is expressed only in such cells and thus
gives a good indication of latent HHV-8 infection. In ad-
dition, LANA interacts with the tumour suppressor pro-
tein p53 and represses its transcriptional activity [32].
Our second assay was developed for vGCR, G-protein cou-
pled receptor, and amplifies a 168 bp fragment. A receptor
that binds several CXC and CC chemokines, vGCR ap-
pears to be constitutively active [33], although some stud-
ies indicate that it is expressed only during lytic
replication [34]. It may contribute to the pathogenesis of
KS by increasing the release of cellular growth factors such
as VEGF [33]. It transforms rodent fibroblasts and induces
expression of angiogenic factors [35].
The final two assays were developed for the genes vBcl-2
and vIL-6. The assay for vBcl-2 amplifies a 216-bp frag-
ment, and for vIL-6 the fragment is 186 bp. vBcl-2 and vIL-
6 are both early lytic genes, as their expression increases
within 10 hours after induction [9]. 
vBcl-2 is a member of the Bcl-2 family, and functional
studies indicate that vBcl-2 prevents Bax-mediated apop-
tosis and thus is an anti-apoptotic protein [36,37]. It is
primarily active during lytic replication and its expression
pattern suggests that it may function to prolong the sur-
vival of cells in which lytic infection is present.
vIL-6 is a secreted cytokine that maintains proliferation of
IL-6-dependent mouse and human mycelia cell lines
[21,38,39] and prevents apoptosis [21,38,40].
NASBA
A NASBA reaction is based on the simultaneous activity of
avian myeloblastosis virus (AMV) reverse transcriptase
(RT), RNase H and T7 RNA polymerase with two oligonu-
cleotide primers to produce amplification of the desired
fragment more than 1012 fold in 90 to 120 minutes
[23,41]. In a NASBA reaction, nucleic acids are a template
for the amplification reaction only if they are single
stranded and located in the primer-binding region. Be-
cause the NASBA reaction is isothermal (41C), specific
amplification of ssRNA is possible if denaturation of dsD-
NA is prevented in the sample preparation procedure. It is
thus possible to pickup mRNA in a dsDNA background
without getting false positive results caused by genomic
dsDNA, in contrast with RT-PCR. In figure 1 a schematic
presentation of the NASBA amplification is given. NASBA
is achieved with the P1 (antisense) – P2 (sense) oligonu-
cleotide set. The overhang on P1 encodes the promoter se-
quence for the T7 RNA polymerase. By using molecular
beacons with the NASBA amplification a real-time detec-
tion system can be generated. Molecular beacons are
stem-and-loop-structured oligonucleotides with a fluores-
cent label at the 5' end and a universal quencher at the 3'
end. They are highly specific for their target and hybridise
with their amplified target RNA when present in a NASBA
amplification reaction to form a stable hybrid [42] at a rel-
ative low temperature (41C).BMC Infectious Diseases 2002, 2 http://www.biomedcentral.com/1471-2334/2/18
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Figure 1
NASBA amplification reaction NASBA amplification reaction with the P1 (anti-sense) – P2 (sense) oligonucleotide primer
set. The overhang on the P1 encodes the promoter sequence for the T7 RNA polymerase. A molecular beacon with a fluoro-
phore and a quencer with the NASBA amplification reaction generates a real-time detection system.
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Standard RNA
The NASBA quantification method is based on a standard
curve with a known input of RNA. For this input we used
in vitro RNA that was transcribed from four different plas-
mids. These plasmids were generated by cloning a specific
PCR product for each of the four target genes, using prim-
er sets located on the borders of the different genes. Prim-
er sequences are shown in table 1. Input for the PCR was
the nucleic acids of the BCP-1 cell line (a cell line contain-
ing HHV-8). The sizes of the four different PCR fragments
were 595 bp, 926 bp, 473 bp, and 589 bp for ORF 73,
vGCR, vBcl-2 and vIL-6, respectively (table 1). Each PCR
fragment was cloned into the TOPO-TA plasmid (Invitro-
gen/ Lifetechnologies, Carlsbad, USA), and after all inserts
were verified by sequencing, the fragments were cloned in
a plasmide, pBluescript SK (Stratagene, La Jolla, USA). In
vitro RNA was generated from these plasmids using T7 or
T3 RNA polymerase, depending on the orientation of the
fragment, and was treated with DNase to remove the plas-
mid. The Q-RNA was purified by RNeasy (Qiagen, Hilden,
Germany), quantified spectrophotometrically, and
checked by eye on agarose gel. The resulting in vitro RNA
was used for the four different standard curves.
Real-time amplification system
NASBA amplification requires a sense and an anti-sense
primer, and for real-time detection a unique beacon is
added to the reaction. We developed molecular beacons
that could hybridise with the known sequences of the four
HHV-8 genes, as shown in table 2. All the beacons have 6-
fluorescine (6-FAM) as the fluorescent label at the 5' end
and a (4-(dimethylamino) phenyl) azo) benzoic acid
(Dabcyl) as universal quencher at the 3' end. A BLAST
analysis revealed that in each case, neither the primers nor
the beacon shared significant homology with any known
nucleotide sequences other than the target gene. The qual-
ity of the different beacons was tested with a melting curve
(from 80C to 20C) and acryl amide gel electrophoresis.
Each reaction consisted of 5 l of the sample RNA and 10
l of NASBA reaction mix. This mix consisted of 80 mM
Tris-HCl [pH 8.5], 24 mM MgCl2, 140 mM KCl, 1.0 mM
DTT, 2.0 mM of each dNTP, 4.0 mM each of ATP, UTP and
CTP, 3.0 mM GTP, and 1.0 mM ITP in 30% DMSO. This
solution also contained the anti-sense and sense primers
for amplification and the molecular beacons used for de-
tection. The final concentration for the primes was 0.1 M
and for the beacons 40 nM.
Table 1: Primers for PCR fragment in plasmids
5' primer 3' primer PCR fragment size
ORF 73 agcccaccaggagataataca tcatttcctgtggagagtccc 595 bp
vGCR gcggatatgactactctggaaact gaggctttggaagagaccgt 926 bp
vBcl-2 atggacgaggacgttttgcct cccaatagcgctgtcattct 473 bp
vIL-6 ggttcaagttgtggtctctctt ggagtcacgtctgggatagagt 589 bp
Table 2: Sequences of the primers and beacons for each of the assays
Primer P1 Anti-sense primer Primer P2 Sense primer Beacon Stem-loop in lowercase italics
ORF73 AG AGA CAA TAC ACA TAT ACA CAA 
TAA G
GAA AGG ATG GAA GAC GAG ATC CA gca cgc AGG AGT AAA GGC AGG CCC 
CGT GTC gc g tgc
vGCR AA CGA GGT TAC TGC CAG ACC CAC 
GT
CAG GCG GAA GGT AAG GGG GGT 
GA
gca cgc TGA TTG TTG CTG TGG TGC 
TGC T gcg tcg
vBcl-2 AA GCG AAA CCA CTG GGG TCC GAT 
TG
GTG AGA TTT CAC AGC ACC ACC 
GGT A
gca cgc TGA CCT TTG GCA GTT TTG 
TGG CC gcg tgc
vIL-6 AG AAC ATA AAA CGA AGC AAA GTG 
TCT CA
GGA AAA TCA GTG ATA AAC GTG GA gca cgc GGA AGA GCT CAA TAA GCT 
GAC TA gcg tgc
U1A AG AGG CCC GGC ATG TGG TGC ATA 
A
CAG TAT GCC AAG ACC GAC TCA GA cgt acg AGA AGA GGA AGC CCA AGA 
GCC A cgt acg
The 3' anti-sense primer is elongated with T7-promotor recognition sequence: AAT TCT AAT ACG ACT CAC TAT AGG GBMC Infectious Diseases 2002, 2 http://www.biomedcentral.com/1471-2334/2/18
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The reaction mixtures were incubated at 65C for 5 min,
and after cooling to 41C for 5 min to allow for primer an-
nealing, 5 l of enzyme mix was added by pipetting into
the lids of the microtubes and subsequently spinning
down. This mix contained, per reaction, 375 mM sorbitol,
2.1 g BSA, 0.08 U RNase H, 32 U T7 RNA polymerase
and 6.4 U AMV reverse transcriptase. Reactions were incu-
bated at 41C for 120 min in a fluorometer (Cytofluor
4000; Perkin-Elmer, Wellesley, Mass.). The RNA ampli-
cons generated in the NASBA process are detected by mo-
lecular beacons [29]. These beacons generate a fluorescent
signal during amplification when hybridising with their
target. The fluorescence is measured continuously during
amplification for real-time monitoring (i.e., as the reac-
tion proceeds). A threshold is determined by setting the
fluorescence emitted in the first 5 measure points as a
background. The time-point at which a reaction rises
above this threshold of detection and becomes positive is
determined. This time-to-positivity (TTP) principle is sim-
ilar to real-time PCR [43]. A calibration curve with 50,
102, 103, 104, 105, 106 and 107 molecules HHV-8 mRNA
was included in each experiment. The number of mRNA
copies per sample input can be extrapolated from the
standard curve. De Baar et al showed that it is possible to
use ttp values for quantification without the use of an in-
ternal calibrator [44].
RNA quantification
For standardisation of the amount of RNA input the U1A
assay was used in each experiment. U1A mRNA encodes
for one of the proteins of the U1 snRNP [45,46]. Because
U1A is constitutively expressed, the amount of U1A
mRNA measured in the samples is an indication of total
RNA input. The mean of 6 assays (variation 0.6 log) was
taken as the input RNA amount of the sample, and sample
input RNA was normalised accordingly. The NASBA con-
ditions for the U1A assay were the same as those for the
HHV-8 assay, with the exception of the final concentra-
tion of the primer (0.2 M) and the beacon (50 nM).
HHV-8 DNA assay
The DNA fractions of the PBMC samples were tested for
the presence of HHV-8 DNA using a nested PCR for ORF
73 described by Goudsmit et al. [47]. As a quantification
of the amount of DNA input, a limited dilution PCR for
the cellular CCR5 gene was used. With limited dilution,
an estimation of copies of HHV-8 DNA was made in rela-
tion to the amount of cells. For both the ORF 73 and the
CCR5 nested PCR, the detection level was 5 molecules in-
put per reaction.
Patient samples
To test our assays in vivo, we selected PBMC samples from
two participants of the Amsterdam Cohort Studies. De-
scribed elsewhere in detail [48,49], they were both HIV-1-
infected men with Kaposi's sarcoma but had very different
disease development. Patient 1 was a 30-year-old man
who was demonstrated to be HIV-1-seropositive in 1995.
In July 1996 he was diagnosed with KS. He did not re-
spond to anti-retroviral or chemotherapy and died in Jan-
uary of 1997 as a result of severe infiltration of KS in both
lungs. Patient 2 is a 36-year-old man who visited our out-
patient clinic in 1992 with an increasing number of KS-re-
lated skin lesions. After he started anti-retroviral therapy
several lesions disappeared and complete remission was
gradually reached over the course of two years. These two
patients were chosen in large part for the diversity in their
course of Kaposi's sarcoma. We tested three samples for
patient 1 and seven samples for patient 2 collected over
time, all taken after diagnosis of KS.
After the frozen PBMC samples were thawed the cells were
collected and resuspended in Trizol™ buffer to isolate
RNA and DNA simultaneously, according to the manufac-
turer's recommendations. Precipitated RNA was redis-
solved in 50 l H2O. For each time-point, a known
amount of cells (7.6–11.1 * 106 cells) were isolated. With
high input of total RNA we found that background RNA
can disturb the amplification if present in large amounts
and it was necessary to dilute the samples. To have a broad
range in the dilution for the RNA quantification in the
NASBA experiments, the samples were diluted 10,100,
and 1000 times. Of these diluted samples 5 l was used
per reaction, and 10 l of reaction mix was added. U1A
mRNA was used as an external standard to compare quan-
tification signals among the different samples.
Results
Sensitivity and specificity
These newly developed assays can be used quantitatively
by testing a standard curve of samples with a known
amount of mRNA molecules within the same experiment
as the unknown samples, then extrapolating the results to
the standard curve. Typical amplification curves could be
plotted in which an increase of fluorescence was observed
until most of the molecular beacon had hybridised with
the synthesised amplicons and the fluorescence reached a
maximum level.
Such an amplification of in vitro synthesised ORF 73 RNA
is shown in the insert in figure 2a. The time-point at which
the fluorescence signal became detectable over the back-
ground i.e., time-to-positivity (ttp), was linear over a
range of at least six orders of magnitude of input RNA
molecules, as shown by the dilution series of in vitro syn-
thesised RNA. In figure 2a the relationship between ttp
values of the standard curve for ORF 73 and the log input
of in vitro RNA is shown. This relationship extended from
107 to 50 molecules input.BMC Infectious Diseases 2002, 2 http://www.biomedcentral.com/1471-2334/2/18
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Figure 2
Standard curves in vitro RNA Figure 2 a-d. Relationship of time-to-positivity (TTP) to HHV-8 mRNA copy number. The
number of mRNA molecules present in the reaction is indicated on the x axis and the ttp value in indicated on the y axis. For
the data obtained with 50, 102 to 107 molecules, the values of TTP are the mean of five replicates of independent experiments.
For the U1A the range of RNA input was 103 to 108. Error bars indicate the standard deviation for the values of ttp. The solid
line was obtained by linear regression analysis of the data from 50 to 107 molecules, and the dotted lines indicate the 95% con-
fidence intervals for the regression. Inserts a-d: Amplification plot of a 10-fold dilution serial dilution of in vitro RNA for ORF
73, vGCR, vBcl-2 and vIL-6. The amount of input RNA 1 * 107, 1 * 106, 1 * 105, 1 * 104, 1 * 103, 1 * 102, 50 and 0 molecules.
Insert e: Amplification plot of a 10-fold dilution serial dilution of U1A in vitro RNA, the amount of input RNA 1 * 108, 1 * 107, 1
* 106, 1 * 105, 1 * 104, 1 * 103 and 0 molecules.
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The dilution series of in vitro RNA showed a detection lev-
el of 50 molecules input. For accurate quantification the
required level is 102 molecules input per assay. The line is
calculated with linear regression analysis. Besides the lim-
it of detection (LOD), the limit of quantification (LOQ)
can be determined. For ORF 73, the LOD is 50 molecules
input (84% pos.) while the LOQ is 102 molecules per re-
action. The linear quantification of the ORF 73 assay was
determined to be between 102 to 107 copies RNA per re-
action (R 2 = 0.96, p < 0.001, fig. 2a). The sensitivity of all
four assays was studied using five serial dilutions. The lin-
ear regression analyses for the other assays are shown in
figure 2b,2c,2d,2e. The assay for vGCR has a very small
standard deviation, and the amplification is linear from
107 to 50 molecules input per reaction (R 2 > 0.99, p <
0.001, fig. 2b). The LOD is 50 molecules (55% pos.) and
the LOQ is 102 molecules per reaction. The assays for both
vBcl-2 and vIL-6 are weaker but still within a workable
range. As above, the linear quantification was between
102 to 107 copies RNA per reaction (R 2 = 0.94 and R 2 =
0.95 respectively, p < 0.001, fig. 2c,2d). For both assays,
the LOD is 50 molecules (72% and 50% pos. respectively)
and the LOQ is 102 molecules per reaction. U1A has a lin-
ear quantification range of 103 to 108 molecules (R2 =
0.99, p < 0.001, fig 2e). The assay for U1A had a sensitivity
of only 103 copies input/reaction, which is feasible due to
the high expression level of U1A.
The specificity of the five assays was tested by spiking each
reaction with 106 molecules of in vitro RNA that the prim-
ers and beacon were not designed for. For example, ORF
73 in vitro RNA did not give a signal with the vGCR assay
(data not shown).
Robustness
In replicate independent experiments, the time-to-positiv-
ity (TTP) value had a linear relationship with the loga-
rithm of the amount of in vitro RNA added in the reaction.
Subsequent experiments used serial 10-fold dilutions of in
vitro RNA (from 107 to 102 and 50 molecules per reaction)
as a standard curve to determine the amount of HHV-8
RNA in samples. The experiments were done on different
days and by different people with no significant variation
in results, which confirmed the robustness of the assays
and also their ease of performance.
Patient samples
To address the functionality and quality of the HHV-8 as-
says in vivo, they were tested on PBMC samples collected
after KS diagnosis from two participants in the Amster-
dam Cohort Studies. In total, 10 frozen samples were an-
alysed. As a positive control, all samples were tested for
the presence of HHV-8 DNA with a nested PCR and were
found to be positive (see Materials and Methods). The
copies of HHV-8 DNA varied between 2 and 2 * 102 per
103 cells (table 3). A relation has been shown between the
HHV-8 DNA levels in PBMC and the extent of Kaposi's
sarcoma [50]. A possible correlation between DNA levels
and mRNA expression should be investigated.
The results of the HHV-8 assays are shown in table 3. Of
the 10 samples, 9 were positive for ORF 73, whereas only
half were positive for vGCR. While vBcl-2 was measured
in 9 out of 10 samples, vIL-6 was detected in approximate-
ly half of the samples. All the samples that were positive
for ORF 73 were also positive for vBcl-2. Surprisingly the
samples were positive for a latent and a lytic gene at the
same time. The variation in expression levels is large both
Table 3: The ratio mRNA of (HHV-8 / U1A)  107
ORF 73 vGCR vBcl-2 vIL-6 HHV-8 DNA copies per 
103 cells
1.1 6,3  105 3,1 3,1 62 20
1.2 92 71 71 - 20
1.3 2,2  102 9,2 3,3  103 1,8  102 200
2.1 2,9  102 -3 , 9    104 -2 0
2.2 2,7  102 -2 , 7    102 2,2  102 2
2.3 5,0  102 2,6  105 3,2  103 25 2
2.4 3,0  102 8,5  103 5,7  105 3,0  103 2
2.5 2,6 102 -4 , 0    102 -2
2.6 41 - 4,1  103 2,6  104 2
2 . 7 ---- 2
Negative samples are shown as -. Samples from patient 1 are numbered 1.1–1.3; samples from patient 2: 2.1–2.7.BMC Infectious Diseases 2002, 2 http://www.biomedcentral.com/1471-2334/2/18
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among the different assays and among the samples. No
clear trend in the expression of HHV-8-specific mRNA can
be distinguished, based on HHV-8 DNA levels, patient, or
disease status.
Discussion
In general the NASBA assay has several advantages over
the PCR technique [51]. The amplification procedure of
the NASBA assay is entirely isothermal and is conducted
at 41C; it does not require thermal cycling instrumenta-
tion. The NASBA product is single-stranded and can there-
fore be readily detected by hybridisation analysis.
Our four real-time NASBA assays offer these benefits and
also the five features that define validation of any assay:
accuracy, sensitivity, precision, robustness, and specificity.
With the use of standard curves in each experiment, accu-
racy is achieved. The sensitivity is determined with a linear
standard curve. The limit of detection (LOD) and the limit
of quantification (LOQ) are determined. For all the HHV-
8 assays, the LOD is 50 molecules per reaction and LOQ
was 100 molecules per reaction. To achieve linear ampli-
fication requires at least 5 concentrations on the linear
portion of the curve. For the HHV-8 assays, the linear
range spans 7 concentrations and for U1A it spans 6 con-
centrations. Quantification was achieved within this line-
ar range of at least six orders of magnitude (102 to 107
molecules per reaction). Within this linear range quantifi-
cation of at least six orders of magnitude (102 to 107 mol-
ecules per reaction) was achieved.
The precision of the assays was measured as the standard
deviation and the confidence interval (fig. 2). We used 5
replicates of 7 different concentrations of the standard
curve. Robustness was determined by having different
people perform the experiments on different days. Specif-
icity was shown with spiking experiments. The lower de-
tection level of the assays was approximately 50 copies per
reaction. The assays work equally well in vivo as in vitro
e.g., for quantification of HHV-8 RNA in PBMCs.
The onset of KS is associated with a high HHV-8 load in
PBMC [19] and this indicates that HHV-8 infected circu-
lating cells play an important role in KS development
[20,52,53]. HHV-8 can infect circulating B cells, mono-
cytes/macrophages, T cells and KS-like spindle cell pro-
genitors [54–56]. In KS lesions B cells are rare or absent,
but monocytes macrophages are abundantly present [52],
this suggest that circulating monocytes may recruit the vi-
rus into tissues or transmit the virus to other cells. Since
lymphocytes and monocytes infiltrating KS lesions can be
productively infected by HHV-8 [20,22], it is important to
look at active infection in the PBMC. PBMCs of two AIDS-
KS patients were selected and analysed for the presence of
HHV-8 mRNA.
In 90% of our samples, ORF 73 mRNA and vBcl-2 mRNA
were detected, whereas for vIL-6 mRNA and vGCR mRNA
were present in 60% and 50%, respectively. The expres-
sion levels of all four genes varied widely. Comparing the
different expression levels of the four HHV-8 genes within
one sample or comparing expression levels of one gene in
one patient did not show an apparent tendency. No clear
trend can be distinguished based on the HHV-8 DNA lev-
els, patient or disease status. Nevertheless the finding of
expression of different HHV8 specific genes in PBMCs is
notable in itself, as it has not been described before. HHV-
8 RNA has been found in tissues, endothelial cells and
spindle cells [18,57,58]. In 90% of fresh KS-affected tis-
sues, HHV-8 RNA has been detected with RT-PCR [59]. In
situ hybridisation and LANA immunohistochemistry have
confirmed HHV-8 gene expression in KS spindle cells
within KS lesions [18,58,60–62]. Expression of lytic HHV-
8 genes has also been documented in monocytes and
macrophages in KS lesions [20].
Conclusion
The assays that were developed work well for the detection
and quantification of HHV-8 specific mRNA. Although no
clear trend in the expression pattern could be distin-
guished the finding of expression of different HHV8 spe-
cific genes in PBMCs is important in itself. As this suggests
that HHV-8 replication takes place in the PBMC. The PB-
MCs we used were obtained from two patients. To draw
conclusions about the clinical and prognostic utility of
these assays more patients and patient samples need to be
analysed. However, as the assays are able to quantify
HHV-8 mRNA in PBMC samples we feel that these real-
time NASBA assays with beacon detection provide tools
for further study of HHV-8 expression in patient material.
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